Abstract 3371: Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays
Jonathan T. Lei(Baylor College of Medicine), Matthew J. Ellis(University of California, Davis), Vikrant Mehta(Baylor College of Medicine), Jack Cuzick(Queen Mary University of London), Meenakshi Anurag(Baylor College of Medicine), Shyam M. Kavuri(Baylor College of Medicine), Eugene F. Schuster(Institute of Cancer Research), Malachi Griffith(Washington University in St. Louis), Jason Kunisaki(James S. McDonnell Foundation), Zachary L. Skidmore(James S. McDonnell Foundation), Catrina C. Fronick(Washington University in St. Louis), Mitch Dowsett(Institute of Cancer Research), Brian Li(Boston Children's Hospital), Nicholas C. Spies(James S. McDonnell Foundation), Robert S. Fulton(St. Jude Children's Research Hospital), Obi L. Griffith(Washington University in St. Louis), Richard Buus(Royal Marsden Hospital), Kim Chu(Queen Mary University of London)
Cited by 0
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
The B73 Maize Genome: Complexity, Diversity, and Dynamics
|Science|2009|4.2k
The complete sequence of a human genome
|Science|2022|3.3k
Somatic mutations affect key pathways in lung adenocarcinoma
|Nature|2008|2.8k